Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency | MicrobiomeTrials← Back to trialsNCT06090669
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-12-19Est. Completion: 2026-10-30
Enrollment target: 71 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United StatesEst. completion Jan 1, 2035
Severe Aplastic AnemiaTelomere Biology Disorders
Inherited Bone Marrow Failure Syndromes
Background:
Bone marrow failure diseases are rare. Much is known about the diseases at the time of diagnosis, but long-…
Bethesda, United StatesEst. completion Feb 4, 2041